Lantheus Holdings (LNTH) Liabilities and Shareholders Equity (2014 - 2026)
Lantheus Holdings (LNTH) reported Liabilities and Shareholders Equity of $2.3 billion for Q1 2026, up 14.18% year-over-year from $2.1 billion in Q1 2025, and up 5.35% quarter-over-quarter from $2.2 billion in Q4 2025.
Lantheus Holdings (LNTH) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $2.3 billion in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $2.3 billion, up 14.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.0 billion (up 11.73% YoY), and the FY2025 annual result was $2.2 billion, up 12.48% from the prior year.
- Liabilities and Shareholders Equity rose to $2.3 billion in Q1 2026 per LNTH's latest filing, from $2.2 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $2.3 billion in Q1 2026 and troughed at $933.2 million in Q1 2022.
- A 5-year average of $1.7 billion and a median of $1.8 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 52.96% in 2022, then increased 9.09% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.3 billion in 2022, then grew by 24.97% to $1.7 billion in 2023, then climbed by 19.94% to $2.0 billion in 2024, then grew by 12.48% to $2.2 billion in 2025, then grew by 5.35% to $2.3 billion in 2026.
- Business Quant data shows LNTH's Liabilities and Shareholders Equity at $2.3 billion in Q1 2026, $2.2 billion in Q4 2025, and $2.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 2.35 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 2.27 Bn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 401.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.35 Bn |
| Dec 31, 2025 | 2.23 Bn |
| Sep 30, 2025 | 2.28 Bn |
| Jun 30, 2025 | 2.12 Bn |
| Mar 31, 2025 | 2.06 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Sep 30, 2024 | 2.05 Bn |
| Jun 30, 2024 | 1.94 Bn |
| Mar 31, 2024 | 1.83 Bn |
| Dec 31, 2023 | 1.65 Bn |
| Sep 30, 2023 | 1.52 Bn |
| Jun 30, 2023 | 1.34 Bn |
| Mar 31, 2023 | 1.35 Bn |
| Dec 31, 2022 | 1.32 Bn |
| Sep 30, 2022 | 1.10 Bn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 933.17 Mn |
| Dec 31, 2021 | 863.78 Mn |
| Sep 30, 2021 | 847.82 Mn |
| Jun 30, 2021 | 857.80 Mn |